Cargando…

Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

BACKGROUND: The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients’ health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients’ HRQoL data, should have established conte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trudeau, Jeremiah J., He, Jianming, Rose, Esther, Panter, Charlotte, Randhawa, Sharan, Gater, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450032/ https://www.ncbi.nlm.nih.gov/pubmed/32851569 http://dx.doi.org/10.1186/s41687-020-00235-4

Ejemplares similares

Understanding and measuring symptoms and health status in asthma COPD overlap: content validity of the EXACT and SGRQ
por: Nelsen, Linda, et al.
Publicado: (2018)

Management of patients with lower-risk myelodysplastic syndromes
por: Brunner, Andrew M., et al.
Publicado: (2022)

The Amblyopia Quality of Life (AmbQoL): Development and Content Validation of a Novel Health-Related Quality of Life Instrument for Use in Adult and Pediatric Amblyopia Populations
por: Webber, Ann, et al.
Publicado: (2023)

EASIX for prediction of survival in lower-risk myelodysplastic syndromes
por: Merz, Almuth, et al.
Publicado: (2019)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
por: Galili, Naomi, et al.
Publicado: (2012)

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
por: Meunier, Mathieu, et al.
Publicado: (2022)

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
por: Hoeks, Marlijn, et al.
Publicado: (2020)

Evaluation of the Content Validity and Cross-Cultural Validity of the Study Participant Feedback Questionnaire (SPFQ)
por: Greene, Alison, et al.
Publicado: (2020)

Abnormal Dendritic Cell-poiesis in Patients With Lower-risk Myelodysplastic Syndromes
por: Sánchez, Ángela, et al.
Publicado: (2020)

Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
por: Volpe, Virginia O., et al.
Publicado: (2021)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome
por: Corrao, Kristen, et al.
Publicado: (2022)

Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)
por: Gater, Adam, et al.
Publicado: (2020)

Assessing the Comparability of Paper and Electronic Versions of the EORTC QOL Module for Head and Neck Cancer: A Qualitative Study
por: Norquist, Josephine, et al.
Publicado: (2017)

Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients
por: Søgaard Helbo, Alexandra, et al.
Publicado: (2015)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
por: Oliva, Esther, et al.
Publicado: (2023)

The endometriosis daily diary: qualitative research to explore the patient experience of endometriosis and inform the development of a patient-reported outcome (PRO) for endometriosis-related pain
por: Guan, Yanfen, et al.
Publicado: (2022)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome
por: Huang, Xin, et al.
Publicado: (2021)

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
por: de Swart, Louise, et al.
Publicado: (2018)

PB2011: TRANSFUSION BURDEN IS AN IMPORTANT PROGNOSTIC FACTOR IN LOWER-RISK MYELODYSPLASTIC SYNDROME
por: Lee, Jungmin, et al.
Publicado: (2023)

Measuring dengue illness intensity: Development and content validity of the dengue virus daily diary (DENV-DD)
por: Jones, Amy M., et al.
Publicado: (2023)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

Myelodysplastic syndromes
por: Hellström Lindberg, Eva
Publicado: (2018)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
por: Amor, Imen Ben, et al.
Publicado: (2023)

Myelodysplastic syndrome: validation of flow cytometry multilineage score system
por: de Araújo, Helena Varela, et al.
Publicado: (2020)

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
por: Butrym, Aleksandra, et al.
Publicado: (2015)

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis
por: Raimbault, Anna, et al.
Publicado: (2016)

Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes
por: Jiang, Lingxu, et al.
Publicado: (2019)

No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki
por: Toriyama, Eo, et al.
Publicado: (2020)

Discontinuation of the renin–angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes
por: Pavlidis, George, et al.
Publicado: (2021)

Is 6-Shogaol an Effective Phytochemical for Patients With Lower-risk Myelodysplastic Syndrome? A Narrative Review
por: Ooi, Soo Liang, et al.
Publicado: (2021)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY
por: Chapuis, Nicolas, et al.
Publicado: (2023)

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes
por: Belickova, Monika, et al.
Publicado: (2016)

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
por: Park, Sophie, et al.
Publicado: (2019)

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
por: Sauta, Elisabetta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_70e97abar3l69io5vbeni7h3rp